GlassScriptPhysician profile
Suzanne Jane Baron
NPI 1619003324
$273,894.11
in general payments reported to CMS, 2019-2025
22 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $27K · 2021: $29K · 2022: $51K · 2023: $41K · 2024: $48K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $81K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Honoraria: $17K · Travel and Lodging: $7,365 · Food and Beverage: $6,604 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,950 · Education: $1,385 · Grant: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $81,342.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,212.25 |
| Honoraria | $17,250.00 |
| Travel and Lodging | $7,365.32 |
| Food and Beverage | $6,603.67 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,950.00 |
| Education | $1,385.00 |
| Grant | $134.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $64,916.69 | 2019-2025 | Sentinel, General - Ct_ic, General - Vascular Access |
| Abbott Laboratories | $52,850.47 | 2019-2025 | Tendyne, Pressurewire, Xience Sierra |
| Medtronic, INC. | $35,495.05 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Edwards Lifesciences Corporation | $34,563.60 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26,426.59 | 2021-2025 | Lifevest |
| Abiomed | $24,334.90 | 2019-2025 | Impella |
| Heartflow, INC. | $12,587.91 | 2024-2025 | |
| Shockwave Medical, INC | $9,725.00 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $4,100.60 | 2021-2022 | |
| Csl Behring | $2,535.00 | 2021 | |
| Janssen Research & Development, LLC | $1,620.00 | 2023-2025 | |
| Croivalve INC | $1,500.00 | 2023 | |
| Recor Medical INC | $900.00 | 2025 | Paradise Ultrasound Renal Denervation System |
| Zoll Circulation INC | $744.00 | 2022-2023 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Medtronic Vascular, INC. | $564.71 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $350.00 | 2022 | |
| Chiesi USA, INC. | $327.44 | 2023-2025 | Kengreal |
| Philips North America LLC | $190.63 | 2021-2023 | |
| Inari Medical, INC. | $116.73 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Corindus INC. | $22.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.